To start your customized experience click the start button
Cancer Types
Quick Links
Award Programs
About Us
Contact Us
Privacy Policy
Terms & Conditions
Face Book
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2017
CURE Communications Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.


Silas Inman
A four-drug combination, including Tecentriq (atezolizumab), Avastin (bevacizumab), carboplatin and paclitaxel, delayed progression or death by 38 percent in patients with advanced non-squamous non–small cell lung cancer (NSCLC), compared to those who were treated with Avastin alone.
CURE Staff
Although ROS1 mutations are quite rare in patients with non-small cell lung cancer (NSCLC), testing for the mutation in all who have the disease is important, as it can play a vital role in determining a treatment plan.
Danielle Bucco
Imfinzi (durvalumab), a PD-L1 inhibitor, is being reviewed for a supplemental biologics license application (sBLA) by the Food and Drug Administration (FDA) for the treatment of patients with stage 3, unresectable non-small cell lung cancer (NSCLC). The sBLA is in light of positive progression-free survival (PFS) results from the phase 3 PACIFIC trial.
David R. Gandara, M.D

David R. Gandara, M.D., UC Davis Comprehensive Cancer Center, discusses how diagnostic and therapeutic changes are happening alongside one another in non-small cell lung cancer.
Jason M. Broderick
Frontline Tagrisso (osimertinib) was granted a priority review to a supplemental new drug application (sNDA) by the Food and Drug Administration (FDA) to treat patients with non-small cell lung cancer (NSCLC) whose tumors have EGFR mutations (exon 19 deletions or exon 21 [L858R] substitution mutations).
Brielle Urciuoli
To raise awareness for the striking effects the disease has on women, the LCRF recently launched two campaigns.
Kristie L. Kahl
Imagine being diagnosed at the age of 21 as a never-smoking individual and college athlete.
THE TERM “BIOPSY” DATES to the 1800s. Tissue biopsies have served as the definitive way to confirm a diagnosis of cancer. However, much like cancer drug development is evolving, so is the way we can detect the disease, categorize it more precisely and, more recently, even pinpoint how to treat it.
Genetic mutations help fuel the growth of cancer tumors in patients. And, in recent years, experts in the medical field have begun to better understand how targeting those mutations can knock out the spread of the disease.
Silas Inman
The combination delated progression or death compared to Avastin and chemotherapy alone, according to Roche, the manufacturer of the anti–PD-L1 and anti–VEGF agents.

Sign In

Not a member? Sign up now!
Continue without login

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment


Healthcare Professional

Not Applicable